D-Penicillamin Add-On Therapy Compared to Risperidone Alone in Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT138801241457N4

Enrollment

Registered

2010-11-02

Start date

2007-01-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Risperidone, 6-8 mg, orally, plus D-penicillamine, 1000 mg/day, and Piridoxine, 100 mg/day, for 6 weeks. Intervention 2: Risperidone, 6-8 mg, orally, plus Placebo, 1000 mg/day, and Pi

Treatment - Drugs

Risperidone, 6-8 mg, orally, plus D-penicillamine, 1000 mg/day, and Piridoxine, 100 mg/day, for 6 weeks

Risperidone, 6-8 mg, orally, plus Placebo, 1000 mg/day, and Piridoxine, 100 mg/day, for 6 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 56 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: diagnosis of schizophrenia according to DSM-IV-TR with two physicians Exclusion criteria: hepatic failure, renal failure, malignancies, pregnancy, drug addiction

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of symptoms. Timepoint: weekly. Method of measurement: PANSS.	—

Secondary

Measure	Time frame
Faster response to risperidone and side effects. Timepoint: weekly. Method of measurement: PANSS, Liver Function Laboratory Tests, and checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mehdi Pourasghar

Mazandaran University of Medical Sciences

me_pourasghar@yahoo.com+98 15 1328 5659

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026